Google
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle Cell Groups, Pfizer Work to Bring African-Americans into Clinical Trials
It’s been nearly half a century since the end of Alabama’s Tuskegee experiment, the infamous 40-year study in which the U.S. government intentionally gave 399 syphilis-infected black men useless placebos — like aspirin and mineral supplements — instead of penicillin, which could have cured them.
Yet suspicions still linger, complicating today’s efforts to recruit African-Americans into clinical trials for sickle cell disease (SCD), which disproportionately affects black people.
Pfizer, with the help of the Sickle Cell Disease Association of America, is trying to change that.
The New York-based pharma giant, which is now recruiting for its own clinical trials in sickle cell disease, recently launched oneSCDvoice, a collaborative digital platform aimed at educating and lending emotional support to people with SCD.
+myBinderRelated Content
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Roald Dahl’s Marvellous Children’s Charity “Everyone’s Business” campaignhttps://www.youtube.com/watch?v=VqdP3Sxa...
-
Robust Clinical and Laboratory Response to Hydroxyurea Using Pharmacokinetically Guided Dosing for Young Children Wi...Hydroxyurea is FDA-approved and now incr...
-
Blood transfusion for preventing primary and secondary stroke in people with sickle cell diseaseBackground:Sickle cell disease is one of...
-
Preventing Strokes in Children with Sickle Cell Diseasehttps://www.youtube.com/watch?v=k6h7cb7S...
-
The Clinical Trial Journeyhttps://www.youtube.com/watch?v=iWqQiJeP...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.